Syndax reports Q3 2025 revenue $45.9M, Revuforj net sales $32M; FDA approval for NPM1m AML on Oct 24

Syndax Pharmaceuticals Inc

2025-Q3 EPS reported -$2.51 revenue$103,624,000

Total revenue $45.9M (Revuforj net $32.0M, +12% vs Q2; Niktimvo collab $13.9M).
Net loss $60.7M ($0.70/sh) vs $84.1M ($0.98/sh) year-ago; cash $456.1M.
Revuforj FDA-approved for R/R NPM1m AML Oct 24, 2025; added to NCCN Guidelines as cat 2A.
Full-year 2025 R&D+SG&A guidance narrowed to $380-$385M; expects to reach profitability.
Total Revuforj prescriptions ~850 in Q3 (+25% vs Q2); Niktimvo net sales reported by Incyte $45.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.